Autopsy report · NCT05769959

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

“Sponsor decision (not related to safety, efficacy or quality).”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 9 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

Renal Cell Carcinoma; Non-small Cell Lung Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Ovarian Neoplasms

Interventions

RO7515629; tocilizumab

Participants

3

Sites

2

Countries

United States

Trials that died the same way

• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
  “sponsor decision (not for safety)” (90% match in meaning)
• A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
  “Sponsor decision, not safety related” (88% match in meaning)
• Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
  “Sponsor decision (not due to safety concerns)” (88% match in meaning)
• An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
  “Sponsor decision; not a safety decision” (87% match in meaning)
• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
  “Sponsor decision, not related to safety concerns” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.